Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.37 (
DNA methyltransferase
)
4,983
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Growing evidence indicates that there is an emerging link between environmental pollution and cardiac hypertrophy, while the mechanism is unclear. The objective of this study was to examine whether
phenanthrene
(
Phe
) could cause cardiac hypertrophy, and elucidate the molecular mechanisms involved. We found that: 1)
Phe
exposure increased the heart weight and cardiomyocyte size of rats; 2)
Phe
exposure led to enlarged cell size, and increased protein synthesis in H9C2 cells; 3)
Phe
exposure induced important markers of cardiac hypertrophy, such as atrial natriuretic peptide, B-type natriuretic peptide, and c-Myc in H9C2 cells and rat hearts; 4)
Phe
exposure perturbed miR-133a, CdC42 and RhoA, which were key regulators of cardiac hypertrophy, in H9C2 cells and rat hearts; 5)
Phe
exposure induced DNA methyltransferases (DNMTs) in H9C2 cells and rat hearts; 6)
Phe
exposure led to methylation of CpG sites within the miR-133a locus and reduced miR-133a expression in H9C2 cells; 7)
DNMT
inhibition and miR-133a overexpression could both alleviate the enlargement of cell size and perturbation of CdC42 and RhoA caused by
Phe
exposure. These results indicated that
Phe
could induce cardiomyocyte hypertrophy in the rat and H9C2 cells. The mechanism might involve reducing miR-133a expression by DNA methylation.
...
PMID:Phenanthrene exposure induces cardiac hypertrophy via reducing miR-133a expression by DNA methylation. 2683 Jan 71